Date: 2015-03-30
Type of information: Collaboration agreement
Compound:
Company: Abbvie (USA - IL) Biomed X (Germany)
Therapeutic area: Neurodegenerative diseases
Type agreement: collaboration R&D
Action mechanism:
Disease: Alzheimer\'s disease
Details: * On March 30, 2015, AbbVie and BioMed X announced that they have entered into a collaboration agreement to establish a research group focusing on new treatment options of tau pathology in Alzheimer\'s Disease. As part of BioMed X\'s new innovation model, outstanding early career scientists from leading academic institutions world-wide are invited to submit original project proposals focusing on intracellular tau processing and clearance, including proteostasis, as well as studies to elucidate how tau processing is affected by Alzheimer\'s disease-related alterations such as elevated oligomeric amyloid-beta, or the genetic factors linked to late onset Alzheimer\'s disease. AbbVie and BioMed X will jointly select the best ideas and research talents to form a new research group within BioMed X\'s open innovation lab on the multi-disciplinary life science campus of the University of Heidelberg. Further details of the agreement and financial terms are not disclosed.
Financial terms:
Latest news:
